Skip to main content
FDA committee recommends Boehringer's nintedanib for approval

Boehringer Ingelheim's Ofev, or nintedanib, indicated as a treatment for systemic sclerosis-associated interstitial lung disease, received a positive opinion from the FDA's Arthritis Advisory Committee recommending the treatment for the agency's approval. If approved, Ofev will become the first treatment to be commercialized for US patients with SSc-ILD.

Full Story: